Nanocarriers improve performance of breast cancer drugs

(Nanowerk News) Researchers from Islamic Azad University produced new drug nanocarriers to improve breast cancer treatment ("In Vitro Evaluation of the Efficacy of Liposomal and Pegylated Liposomal Hydroxyurea").
In case the drug passes complementary tests successfully, it can be used in medical and pharmaceutical industries.
Breast cancer is one of the most common types of cancers among women. Hydroxyurea (UH) is a chemical that is used for the treatment of this type of cancer in chemotherapy. Efforts have been made in this research to increase the performance of hydroxyurea drug by using nanotechnology and by producing a new carrier. It has also been tried to reduce the undesired effects of the drug as much as possible.
In this research, liposome nanocarriers and pegylated liposome have been produced through reverse phase vaporization process. The nanocarriers are able to carry significant amount of hydroxyurea drug to cancer cells. The toxicity of the produced nanocarriers is less in laboratorial conditions than when the drug is used solely.
Alavi, one of the researchers, explained how the nanocarrier was produced, and said, “The process to liposomate drugs is a new approach for increasing the properties of treatment proteins. In this research, determined ratio of lecithin and cholesterol were mixed, and hydroxyurea drug was added to it later. In order to increase the stability, performance and solubility of the produced nanocarrier, the formulation was pegylated by using polyethylene glycol 2000. Dialysis method was used to study the pattern of drug release from nanoliposomes on breast cancer cells.”
Source: INIC
Subscribe to a free copy of one of our daily
Nanowerk Newsletter Email Digests
with a compilation of all of the day's news.
These articles might interest you as well: